Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 480

Sort by

Sort Order Select

Journal Articles

Very long chain fatty acid metabolism is required in acute myeloid leukemia

Matthew Tcheng, Alessia Roma, Nawaz Ahmed, Richard W. Smith, Preethi Jayanth, Mark D. Minden, Aaron D. Schimmer, David A. Hess, Kristin Hope, Kevin A. Rea, Tariq A. Akhtar, Eric Bohrnsen, Angelo D’Alessandro, Al-Walid Mohsen, Jerry Vockley, Paul A. Spagnuolo

Blood (2021) 137 (25): 3518–3532.

https://doi.org/10.1182/blood.2020008551

Published: 2021

Includes: Supplemental data

Journal Articles

PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors

Rana Gbyli, MS, Yuanbin Song, MD, Wei Liu, PhD, Yimeng Gao, PhD, Namrata S Chandhok, MD, Xiaoying Fu, MD, Xiaman Wang, MD PhD, Amisha Patel, MS, Ranjini Sundaram, PhD, Toma Tebaldi, PhD, Giulia Biancon, PhD, Anastasia Ardasheva, BS, Ashley Qin, Mukhtar Sadykov, MD, Padmavathi Mamillapalli, BS, Richard Flavell, PhD, Thomas Prebet, MD PhD, Ranjit Bindra, MD PhD, Stephanie Halene, MD

Blood (2019) 134 (Supplement_1): 4222.

https://doi.org/10.1182/blood-2019-130814

Published: 2019

Journal Articles

Inhibiting Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Induces Selective Leukemia Cell Death

Matthew Tcheng, BSc, Alessia Roma, BSc, Nawaz Ahmed, MSc, Richard Smith, PhD, Preethi Jayanth, PhD, Mark D. Minden, MD PhD, Rose Hurren, BSc, Aaron D Schimmer, MD PhD, Gale Bozzo, PhD, David Hess, PhD, Kristin Hope, PhD, Kevin Rea, MSc, Tariq A. Akhtar, PhD, Al-Walid Mohsen, PhD, Jerry Vockley, MD PhD, Paul A. Spagnuolo, PhD

Blood (2019) 134 (Supplement_1): 3922.

https://doi.org/10.1182/blood-2019-122262

Published: 2019

Journal Articles

Improved Overall Survival with Enasidenib Compared with Standard of Care Among Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH2 Mutations: A Propensity Score Matching Analysis Using Data from the AG221-C-001 Trial and Two Data Sources from France and Germany

Stephane De Botton, Joseph M Brandwein, MD, Eytan M. Stein, MD, Andrew H. Wei, Daniela Weber, Arnaud Pigneux, Nicolas Boissel, MD PhD, Peter Paschka, MD, Konstanze Döhner, Salem Abi Nehme, Mark G. Frattini, MD, Roland Marion-Gallois, Jixian (Jason) Wang, Chris Cameron, Muhaimen Siddiqui, Rana A. Qadeer, Hartmut Döhner

Blood (2019) 134 (Supplement_1): 3893.

https://doi.org/10.1182/blood-2019-122700

Published: 2019

Journal Articles

Meds433, a New Dihydroorotate Dehydrogenase Inhibitor, Induces Apoptosis and Differentiation in Acute Myeloid Leukemia

Valentina Gaidano, MD, Paola Circosta, PhD, Alessandro Cignetti, MD PhD, Mohammad Houshmand, Nicoletta Vitale, PhD, Stefano Sainas, PhD, Agnese Pippione, PhD, Manuela Marraudino, PhD, Brigitta Bonaldo, MD, Marta Giorgis, PhD, Donatella Boschi, PhD, Marco Lucio Lolli, PhD, Giuseppe Saglio, MD

Blood (2019) 134 (Supplement_1): 3942.

https://doi.org/10.1182/blood-2019-128085

Published: 2019

Journal Articles

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Namrata S Chandhok, MD, Wei Wei, MD PhD, Ranjit Bindra, MD PhD, Stephanie Halene, MD, Yu Shyr, Jing Li, PhD, Michael Berens, PhD, Chris Karlovich, PhD, S. Percy Ivy, MD, Thomas Prebet, MD PhD

Blood (2019) 134 (Supplement_1): 3909.

https://doi.org/10.1182/blood-2019-129168

Published: 2019

Journal Articles

Targeting DHODH with AG-636 Induces Apoptosis and Differentiation and Inhibits Mitochondrial Function in AML, Translating into Anti-Tumor Efficacy in Vitro and i n Vivo

Zhihong Zeng, Natalia Baran, PhDMD, Sergej Konoplev, Antonio Cavazos, Qi Zhang, Vinitha Mary Kuruvilla, MSc, Philip Lorenzi, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD, Courtney D. DiNardo, MDMSc, Joshua Murtie, Danielle Ulanet, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 3911.

https://doi.org/10.1182/blood-2019-125469

Published: 2019

Journal Articles

Serum Albumin Is an Independent Factor Predicting Survival in Patients with Peripheral T Cell Lymphoma: A Multi-Institutional Study from the Latin American Working Group for Lymphomas (GELL)

Henry Idrobo, MD, Brady E. Beltrán, MD, Luis Villela M, Marialejandra Torres Viera, MD, Victoria Otero, MD, Lorena Fiad, MD, Camila Peña, MD, Denisse A. Castro, MD, Yesenia M. Huerta- Collado, MD, Sally Rose Paredes, MD, Ivan Perdomo, MD, Pilar León, MD, Christine Rojas, MD, Virginia Abello, MD, Monica Osuna Pérez, MD, Juan Esteban Garcia-Robledo, MD, Luis E Malpica Castillo, MD, Eduardo Sotomayor, MD, Jorge J. Castillo, MD

Blood (2019) 134 (Supplement_1): 4047.

https://doi.org/10.1182/blood-2019-123588

Published: 2019

Journal Articles

The GPR68/BCL2 Axis Remodels Metabolism in AML By Relocating Calcium

Xiaofei He, B.S., Caleb Hawkins, B.S., Lauren Lawley, B.S., Mark Wunderlich, MS, Benjamin Mizukawa, Xiang-ming Zha, PhD, Stephanie Halene, MD, Jing Fang, MD PhD

Blood (2019) 134 (Supplement_1): 2661.

https://doi.org/10.1182/blood-2019-125455

Published: 2019

Journal Articles

Discovery of a Novel Dihydroorotate Dehydrogenase Inhibitor That Induces Differentiation and Overcomes Ara-C Resistance of Acute Myeloid Leukemia Cells

Satoshi Kitazawa, PhD, Yukiko Ishii, PhD, Keiko Makita-Suzuki, Koichi Saito, PhD, Kensuke Takayanagi, Hiromi Sugihara, Shun Matsuda, PhD, Takayuki Yamakawa, PhD, Yasuhiro Tsutsui, Tadashi Tanaka, Tomohisa Hatta, PhD, Tohru Natsume, PhD, Toru Kondo, PhD, Yuichi Ishikawa, MD PhD, Shinji Hagiwara, PhD, Hitoshi Kiyoi, MD PhD

Blood (2019) 134 (Supplement_1): 2663.

https://doi.org/10.1182/blood-2019-121869

Published: 2019

Journal Articles

Glycolytic Biomarkers Predictive of Transformation in Patients with Follicular Lymphoma

Ida Monrad, MSc, Charlotte Madsen, Kristina Lauridsen, Bent Honoré, Trine Lindhardt Plesner, Stephen Hamilton-Dutoit, MD, Francesco d'Amore, MD, Maja Ludvigsen, MSc, PhD

Blood (2019) 134 (Supplement_1): 2805.

https://doi.org/10.1182/blood-2019-122651

Published: 2019

Journal Articles

AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

Pau Montesinos Fernandez, MD PhD, Christian Recher, MD PhD, Vadim Doronin, MD, Rodrigo T. Calado, MD PhD, Jun Ho Jang, MD PhD, Yasushi Miyazaki, MD PhD, Jianxiang Wang, MD, Diego A Gianolio, PhD, Scott R. Daigle, MS, Thomas Winkler, MD, Vickie Zhang, PhD, Peter Paschka, MD

Blood (2019) 134 (Supplement_1): 2593.

https://doi.org/10.1182/blood-2019-123045

Published: 2019

Journal Articles

Loss of FLT3 Sensitizes Myeloid Cells to Differentiation Via DHODH Inhibition

Amy N Sexauer, MD PhD, Brian Do, David B Sykes, MD PhD

Blood (2019) 134 (Supplement_1): 2712.

https://doi.org/10.1182/blood-2019-128910

Published: 2019

Journal Articles

Multicentre, Open Label, Randomized Phase III Study of Cpi-613 ® (devimistat) in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (≥ 60 years) with Relapsed / Refractory Acute Myeloid Leukemia (AML) - Armada 2000 (AML003) Trial

Timothy S. Pardee, MD PhD, Sanjeev Luther, MBA, Marc E. Buyse, ScD, Bayard L Powell, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 2658.

https://doi.org/10.1182/blood-2019-129377

Published: 2019

Journal Articles

Superiority of IFN Versus HU Using a Novel Biomarker-Based Tool for Assessment of Disease Burden in MPNs

Vibe Skov, PhD, Marc JB Dam, Rasmus K Pedersen, Morten Andersen, PhD, Trine Alma Knudsen, MD, Zamra Sajid, Lasse Kjær, PhD, Christina Ellervik, MD PhD, Hans Hasselbalch, MD, Johnny T Ottesen, PhD

Blood (2019) 134 (Supplement_1): 2972.

https://doi.org/10.1182/blood-2019-126819

Published: 2019

Journal Articles

Dual Targeting of ALDH1 and ALDH3: A Promising Therapeutic Approach in Acute Myeloid Leukemia

Mileidys Perez-Alea, Sr., PhD, Julien Colle, Jr., MD, Muhube Yazir, Jr., MSc, Céline Baier, Jr., PhD, Yasmine Labiad, PhD, Isabelle Arnoux, Sr., Hematologist, Geoffroy Venton, Jr., PhD MD, Guillaume Guillaume, MSc, Ismail Ceylan, MSc, Regis T. Costello, Sr., MD PhD

Blood (2019) 134 (Supplement_1): 3364.

https://doi.org/10.1182/blood-2019-126484

Published: 2019

Journal Articles

Inhibition of De Novo Pyrimidine Nucleotide Synthesis By the Novel DHODH Inhibitor PTC299 Induces Differentiation and/or Death of AML Cells

Marla Weetall, PhD, Kensuke Kojima, MD PhD, Sujan Piya, PhD, Christopher Trotta, PhD, John Baird, PhD, Kylie O'Keefe, Bansri Furia, Gautam M. Borthakur, MD, Robert Spiegel, MD

Blood (2019) 134 (Supplement_1): 5152.

https://doi.org/10.1182/blood-2019-124569

Published: 2019

Journal Articles

Synergistic Effect of DHODH Inhibitor PTC299 with DNA Demethylating Agent Decitabine in Myelodysplastic Syndromes

Kensuke Kayamori, Cheng Zhong, Daisuke Shinoda, MD, Shuhei Koide, PhD, Motohiko Oshima, PhD, Yaeko Nakajima-Takagi, PhD, Naoya Mimura, MD PhD, Ryoji Ito, Kaoru Tohyama, MD PhD, William Lennox, Marla Weetall, PhD, Josephine Sheedy, BS, MSc, Emiko Sakaida, MD PhD, Koutaro Yokote, MD PhD, Atsushi Iwama, MD PhD

Blood (2019) 134 (Supplement_1): 5407.

https://doi.org/10.1182/blood-2019-125200

Published: 2019

Journal Articles

Hereditary Hemolytic Anemias Other Than Thalassemia: Single Center Experience

Gul Nihal Ozdemir, MD, Mehmet Akif Kilic, MD

Blood (2019) 134 (Supplement_1): 4855.

https://doi.org/10.1182/blood-2019-121702

Published: 2019

Journal Articles

The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies

Blood (2019) 134 (Supplement_1): 877.

https://doi.org/10.1182/blood-2019-131255

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Very long chain fatty acid metabolism is required in acute myeloid leukemia

PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors

Inhibiting Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Induces Selective Leukemia Cell Death

Improved Overall Survival with Enasidenib Compared with Standard of Care Among Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH2 Mutations: A Propensity Score Matching Analysis Using Data from the AG221-C-001 Trial and Two Data Sources from France and Germany

Meds433, a New Dihydroorotate Dehydrogenase Inhibitor, Induces Apoptosis and Differentiation in Acute Myeloid Leukemia

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Targeting DHODH with AG-636 Induces Apoptosis and Differentiation and Inhibits Mitochondrial Function in AML, Translating into Anti-Tumor Efficacy in Vitro and i n Vivo

Serum Albumin Is an Independent Factor Predicting Survival in Patients with Peripheral T Cell Lymphoma: A Multi-Institutional Study from the Latin American Working Group for Lymphomas (GELL)

The GPR68/BCL2 Axis Remodels Metabolism in AML By Relocating Calcium

Discovery of a Novel Dihydroorotate Dehydrogenase Inhibitor That Induces Differentiation and Overcomes Ara-C Resistance of Acute Myeloid Leukemia Cells

Glycolytic Biomarkers Predictive of Transformation in Patients with Follicular Lymphoma

AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

Loss of FLT3 Sensitizes Myeloid Cells to Differentiation Via DHODH Inhibition

Superiority of IFN Versus HU Using a Novel Biomarker-Based Tool for Assessment of Disease Burden in MPNs

Dual Targeting of ALDH1 and ALDH3: A Promising Therapeutic Approach in Acute Myeloid Leukemia

Inhibition of De Novo Pyrimidine Nucleotide Synthesis By the Novel DHODH Inhibitor PTC299 Induces Differentiation and/or Death of AML Cells

Synergistic Effect of DHODH Inhibitor PTC299 with DNA Demethylating Agent Decitabine in Myelodysplastic Syndromes

Hereditary Hemolytic Anemias Other Than Thalassemia: Single Center Experience

The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only